ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial
ImmunAbs Inc. (www.immunabs.com) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.
ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoimmune diseases, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH). The complement inhibitors drug market showed its growth potential by achieving an average annual growth rate of 20.7% and a market size of USD $ 5.1 billion in 2020 and is expected to grow to USD $19 billion by 2027.
Paroxysmal nocturnal hemoglobinuria is one example of complement-mediated autoimmune diseases where the membrane proteins protecting the red blood cells from complement activation are lost due to mutations, which results in red blood cells being destructed by the complements. Due to insufficient inhibition of complements shown by currently approved complement inhibitors, SolirisⓇ and UltomirisⓇ, patients who receive these drugs still suffer from the residual symptoms of PNH, which include anaemia, fatigue, and decreased productivity at work.
ImmunAbs’ new complement therapeutic IM-101 targets the safest and most potent component of the complement system, complement C5. IM-101 has been shown to completely inhibit complement activation, and thus is expected to alleviate the symptoms that persist with the standard of care. ImmunAbs will initiate a phase 2a clinical trial in the United States in 2024.
“This is a historical milestone for ImmunAbs.” said Dr. DongJo Kim, the company’s CEO. “We are delighted to see IM-101’s efficacy in humans which has been proven in our ex vivo study. We hope that our IM-101 will reach patients who may suffer from symptoms that persist due to insufficient complement inhibition by the current treatments.”
About ImmunAbs Inc.
ImmunAbs Inc. was established in 2017 by experts of global standard antibody therapeutics development. The vision is "Hope for Patients, Dreams for All." Currently, ImmunAbs has several antibody therapeutics in global standard development for autoimmune diseases, diabetic retinopathy, and metabolic syndrome. ImmunAbs successfully raised KRW 18.1 billion from Seed to series A funding in 2021 and got a non-clinical study national grant for developing IM-101 from Korea Drug Development Fund in November last year.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005380/en/
Contact information
HyunJung Jung
Business Development Manager
Hyunjung.Jung@ImmunAbs.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Launches Daily Options on the CAC 40 ® Index2.5.2024 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the availability of Daily Options on the CAC 40® index, further expanding Interactive Brokers’ robust product suite. Daily Options on the CAC 40® index provide experienced investors with another means to execute short-term trading strategies and manage exposure to the French stock market. Milan Galik, Chief Executive Officer of Interactive Brokers, commented on the launch, "We are pleased to offer Daily Options on the CAC 40® index, which will allow our clients to balance risk and swiftly adjust their portfolios in response to market movements. At Interactive Brokers, we strive to equip our clients with an array of products to find global opportunities, and this new offering underscores our commitment to providing traders with comprehensive product solutions.” Daily Options on the CAC 40® index cater to growing demand from institutional and retail investors for options with daily expirations. The
AMRA Medical’s Muscle Composition Analysis Used to Evaluate the Effect of Liraglutide Treatment in Obesity2.5.2024 15:35:00 CEST | Press release
AMRA Medical - a health informatics and precision medicine company that is pioneering body composition research through gold-standard MRI-based analysis platforms - collaborated on a study driven by University of Texas Southwestern and University Hospital Cleveland to publish new data revealing the effect of liraglutide treatment on muscle composition in adults with obesity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502719692/en/ Credit: Collaboration with Dr. Ian J Neeland, University Hospitals Cleveland. Data from NCT03038620 (ClinicalTrials.gov identifier) analysed with AMRA® Researcher The analysis included 128 diabetes-free adults with obesity who received a lifestyle intervention in addition to being randomized to either a liraglutide (n = 73) or a placebo (n = 55) treatment group. Using the proprietary MRI-based AMRAⓇ Researcher, baseline and follow-up muscle composition analyses were performed, with the prima
Brightcove Integrates New AWS-Powered Generative AI Solution to Enhance Its Award-Winning Customer Service2.5.2024 15:00:00 CEST | Press release
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today shared it has implemented Amazon Q Business, a new generative AI assistant on Amazon Web Services (AWS). Using its own public documentation, product, and release notes, Brightcove is leveraging the new assistant internally for real-world use cases applicable to the media and entertainment technology sector. Brightcove is tapping into the technology to build a program to equip its global services and customer success team to further bolster its award-winning customer service. As an early adopter of Amazon Q, Brightcove has launched the “Brightcove Expert Bot,” an AI-powered chatbot embedded into the internal tools, as a new resource for the customer and product support teams. Streamlining its customer support processes enables employees to quickly and effectively find relevant information, solve technical cases, analyze support requests, summarize support tickets, and use those results to help recomm
Power2Drive Europe: Contributing to the Energy Transition With Bidirectional Charging2.5.2024 14:39:00 CEST | Press release
E-mobility is about much more than driving on climate-neutral electricity from renewable sources. The batteries of electric vehicles can be used as temporary storage. And it’s not just vehicle owners who benefit from this: In the medium-term, bidirectional charging can take the burden off distribution grids while making them more flexible. Power2Drive Europe, the international exhibition for charging infrastructure and e-mobility, showcases the latest state of the art. As part of The smarter E Europe, the continent’s largest alliance of exhibitions for the energy industry, it will take place from June 19–21, 2024, at Messe München. The Power2Drive Europe Conference, the industry's meeting point and forum for exchange and discourse among experts, stakeholders, and thought leaders in the new mobility sector, kicks off one day earlier. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502196803/en/ Power2Drive Europe 2024 highl
Owlet Announces European Medical Certification of Dream Sock Ⓡ2.5.2024 14:37:00 CEST | Press release
Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, announces the EU medical device certification of Dream Sock. This EU-CE-Mark certification, issued by Owlet’s EU notified body, signifies that Owlet’s Dream Sock has been assessed and certified to meet safety and health requirements set out under EU medical device legislation. With this certification, Owlet plans to expand its medical-device product portfolio to even more caregivers around the world. This EU medical device certification follows two marketing authorizations from the U.S. Food and Drug Administration (the “FDA”), for Dream Sock, with new medical technology for healthy infants over-the-counter without a prescription, and for BabySatⓇ, a prescription-only pulse oximeter designed for use with babies that have a pre-existing medical condition. “Our mission to be there for every parent and every baby becomes even more realized with the European medical certification for Dream Sock,” sa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom